Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 4 days ago

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.

Personalized TAK-660 prophylaxis may prevent bleeds in severe haemophilia A

Audrey Abella
13 Aug 2020
Findings from the PROPEL* trial presented at ISTH 2020 suggest that a personalized prophylaxis with rurioctocog alfa pegol (TAK-660) may prevent bleeds in patients with severe haemophilia A.
 
“Recent data suggest personalizing [TAK-660] dosing can better control/prevent bleeds without compromising [its] efficacy or safety … [Our findings] support the feasibility and efficacy of personalized TAK-660 prophylaxis by … targeting elevated factor VIII (FVIII) levels with pharmacokinetic (PK)-tailored dosing,” said the researchers.
 
Ninety-five participants aged 12–65 years received PK-guided TAK-660 prophylaxis targeting either 1–3 (reference; n=52) or 8–12 percent (elevated) FVIII trough activity levels (n=43) for 12 months. [ISTH 2020, abstract PB0920]
 
Total annualized bleeding rates (ABRs) were lower with the elevated vs the reference FVIII level at an FVIII half-life of 6 to <12 hours (0.7 vs 3.5) and 12 to <18 hours (1.0 vs 2.5). Spontaneous ABRs were also lower with the elevated vs the reference FVIII levels at the same points as above (0.3 vs 2.8 and 0.6 vs 0.9, respectively), and even at 18 to <36 hours (0.5 vs 1.2).
 
Spontaneous joint and injury-related ABRs were also lower with the elevated vs the reference FVIII levels, be it among those with 6 to <12 hours (0.15 vs 1.9 [spontaneous] and 0.5 vs 0.9 [injury-related]) or 12 to <18 hours of FVIII half-life (0.3 vs 0.5 and 0.4 vs 1.3, respectively).
 
“[These imply that] patients with shorter FVIII half-life had better bleed prevention with [elevated FVIII trough activity levels] … These benefits may be especially important for patients requiring higher FVIII [trough] activity levels because of active lifestyles and increased risk of injury-related bleeds,” said the researchers.
 
Preserving joint health
In a post hoc analysis evaluating target joint** (TJ) resolution, mean ABR point estimates during the second half of the trial were lower among participants who had no TJs (n=26) with the elevated vs the reference FVIII levels (1.5 vs 2.6 [total], 0.1 vs 1.3 [spontaneous], and 0.0 vs 1.2 [spontaneous joint ABR]). Similar results were observed among those with ≥1 TJs (0.9 vs 2.4, 0.5 vs 1.3, and 0.5 vs 1.2, respectively). [ISTH 2020, abstract PB0921]
 
The second half of the trial also saw greater reductions in mean TJ ABRs in both the elevated and the reference arms (0.2 and 0.1) compared with the first 6 months of the trial (0.7 and 0.5).
 
“[These findings suggest that elevated] FVIII troughs was associated with reduced bleeding into TJs [and] ABRs irrespective of baseline TJ status … [These] results show the clinical benefit of elevating FVIII troughs with TAK-660 for TJ resolution, an important consideration for joint health in haemophilia A,” said the investigators.
 
A tailored approach
“Because every patient is unique, there is no ‘one-size-fits-all’ approach to haemophilia care. We are committed to improving outcomes and quality of life for each person living with a bleeding disorder,” said co-author Dr Carmen Escuriola-Ettingshausen from the Haemophilia Centre Rhein Main in Mörfelden-Walldorf, Germany, in a press release.
 
“[Taken together, these] data … demonstrate the value that innovative, personalized approaches provide to the management of haemophilia,” she added.
 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Oct 2020
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Roshini Claire Anthony, 4 days ago

Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.

09 Nov 2020
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
07 Aug 2020
Concomitant treatment with a nonsteroidal anti-inflammatory drug (NSAID) following myocardial infarction (MI) is associated with a higher risk of cardiovascular and bleeding events, a study has shown.